





Now 60% Off Whole Genome Sequencing Tests

DNA influences many aspects of health, including disease risk and medication response. Whole Genome Sequencing is the most comprehensive DNA test for identifying known and potential genetic variants linked to both — empowering you to make informed decisions and take charge of your health.

No matter where you are on your journey, knowledge is power . . .

Benefits of Testing

- Capture all 22,000 genes
- Proactive and informed approach
- Understand genetic health risks
- Empower early intervention
- · Personalized health plan



FOR ADULTS

\$ 995 (Regularly \$2750)

Analyze 6,000 genes known to be associated with adult-onset conditions and drug sensitivities

- At home saliva kit
- Test for healthy adults
- Actionable Insights

60% Off Ends 9/3/25

USE PROMO CODE: WGS995AD



Scan to learn more

60% Off Ends 9/3/25

USE PROMO CODE: WGS995NB



Scan to learn more

FOR NEWBORNS


\$ 995 (Regularly \$2500)

Analyze 2,500 genes known to be associated with childhood-onset conditions and drug sensitivities

- Requires Cord Blood Banking
- Early Insights. Early Action.
- Re-analyze sample in future







reality.

Why do families choose Whole Genome Sequencing with ViaCord?

Convenient

We make accessing this valuable information is easy. Order online at viacord.com or call (866) 258-5173.

- Adults: We ship you a simple at home saliva collection kit with return shipment labels.
- Newborns: The test is run on a small sample of collected cord blood (cord blood banking is required.)

Take 60% off and start your journey toward better health insights!

Hurry, Offer Ends 9/3/25

Trusted Results

Whole Genome Sequencing tests are performed by Revvity Omics, ViaCord's sister company and a global leader in genomic testing. Our connection allows us to bring families innovative and futurefocused health solutions.

Genetic Services Included

ViaCord teams up with Genome Medical, the country's leading telehealth genetics care company, to provide physician and genetic counselor services at no extra cost. Scan the QR code to learn more about how ViaCord and Genome Medical work together.



Learn More



DISCOVER THE POWER

Whole Genome Sequencing



1 in 12 apparently healthy newborns

A retrospective study published in the Journal of American Medical Association (JAMA) found 1 in 12 apparently healthy newborns who used ViaCord's Whole Genome Sequencing carried genetic findings that could impact their health from an early age. 47% of these findings were associated with health conditions that could benefit from early intervention and medical management. ¹



1 in 5 healthy adults

An analysis of Whole Genome Sequencing (WGS) in healthy adults in the primary care setting found that 1 in 5 had a previously unrecognized variant associated with a rare disease, according to a study published in Annals of Internal Medicine. ^{2.}

QUESTIONS? CALL VIACORD AT (866) 258-5173 OR VISIT VIACORD.COM TO LEARN MORE.

Disclaimer: Promo valid 8/17/25-9/3/25. Whole Genome Sequencing (Adult and Newborn) testing services are provided by ViaCord's sister brand Revvity Omics. This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals. DNA plays a significant role, it's not the only factor that determines our health and wellbeing. Environmental factors, lifestyle choices, and other influences also contribute. References: 1. ViaCord's Whole Genome Sequencing 1 in 12 apparently healthy newborns carried genetic findings that could impact their health from an early age. Balciuniene J., Liu R, Bean L., et al. At-Risk Genomic Findings for Pediatric-Onset Disorders From Genome Sequencing vs Medically Actionable Gene Panel in Proactive Screening of Newborns and Children. JAMA Netw Open. 2023;6(7):e2326445. doi:10.1001/jamanetworkopen/fullarticle/2807782.2. Whole Genome Sequencing Adults 1 in 5 had a previously unrecognized variant with potential risk for a rare inherited disease. Jason L. Vassy, Kurt D. Christensen, Erica F. Schonman, et al; for the MedSeq Project. The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial. Ann Intern Med.2017;167:159-169. [Epub 27 June 2017]. doi:10.7326/M17-0188 https://www.acpjournals.org/doi/10.7326/M17-0188 Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells have not been used in treatment yet. Research is ongoing. Genomic testing services are not for use in Diagnostic Procedures. The content shall not be used to